If the sales targets are then achieved in a sequence of 4 quarters within the next seven years, the corresponding milestones are due. Bayer advanced talks with Monsanto's management and subsequently raised its off by $3 billion, to more than $65 billion - which represented a 2 percent increase on its previous offer. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Novartis ADR sees its Relative Strength Rating reach the 80-plus Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Opiant pharmaceutical (Opiant presentation). Axsome is also developing a late-stage migraine candidate called AXS-07, along with a fibromyalgia candidate called AXS-14. I'm not a drug abuse, public health or biotech expert, and it is challenging to say whether these sale targets are achievable. Clicca su Gestisci impostazioni per maggiori informazioni e per gestire le tue scelte. The merger trades at a slight negative spread before taking into consideration the CVR, so let's take a look at that: Each CVR entitles the holder thereof to receive four contingent cash payments with an aggregate maximum amount payable of $8.00, without interest (each, a Milestone Payment) if the following milestones are achieved: $2.00 per CVR upon achievement of net sales of OPNT003 of $225 million or more during any period of four consecutive quarters prior to the seventh anniversary of the U.S. commercial launch of OPNT003. With multiple partnerships in place and a regulatory filing on the near-term horizon, the stock should roar back to life in 2022. The average yield of the Dow has sunk to 2.1%. your financial adviser and does not provide any individualized investment advice to you. Amgen acquired ChemoCentryx in a $4 billion deal in October, while J&J earlier this month announced a $16.6 billion bid for Abiomed. The drug, approved by the U.S. Food and Drug Administration (FDA) in November 2018, is starting to look like a blockbuster therapy. And following the big news about Aphria and Tilray combining their companies, there's a new deal that's making waves in the cannabis sector. This happens a lot when pharma or biotech companies with important unapproved assets get bought. BREAKING: Another Tech Giant Plans Massive Layoffs. In early February, Merck proposed a buyout at a price of $40 per share, which it revised two days later to $50 per share. AmgenacquiredChemoCentryx in a $4 billion deal in October, while J&J earlier this monthannounceda $16.6 billion bid for Abiomed. After all, the richest deals in this space have generally come in at around six to eight times peak estimated revenue. Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today. Then, after a failed attempt to buy Allergan (NYSE: AGN) last year, Valeant Pharmaceuticals (NYSE: VRX) announced plans to buy Salix Pharmaceuticals (NASDAQ: SLXP) for $10 billion. 2. The information and content are subject to change without notice. It is not my favorite merger with CVR because of 1) the HSR refiling, 2) OPNT003 isn't approved yet, and 3) I'm not quite sure how much better the product will be compared to the incumbent 4) It also appears Narcan has some branding power which means it may take time to acquire market share even if the product is solid. Follow Allison Gatlin on Twitter at @IBD_AGatlin. Horizon Therapeuticssaid on Tuesday its board was engaged in highly preliminary discussions with three pharmaceutical giants for potential takeover offers, sending its shares surging 31% in extended trading. GW Pharmaceuticals is the biggest player in pharmaceutical uses of cannabis, with a market cap of $3.9 billion, making it the sixth-largest marijuana-related stock in the world. San Diego-based ACADIA Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs that address unmet medical needs in central February started off with. Why is Alnylam a possible takeover target? The data showed PT-101 was well-tolerated and selectively activated the immune cells Pandion aimed to target. Amgen declined to comment on the talks, while Sanofi and Janssen Global were not immediately available. No wonder Jazz wants to get in on the hype. When you look at the fact that Jazz is expected to grow earnings at a near-25% annualized rate over the next half decade, its hard not to like the pharma companys prospects. A lot will depend on how much better the product is and if it justifies a premium price. A wave of patent expirations for top-selling drugs such as Eliquis, Humira, and Opdivo is set to hit the industry over the course of the current decade. I wrote this article myself, and it expresses my own opinions. While about two dozen companies showed some interest in Pandion's work between 2018 and 2020, only Merck and one other "global pharmaceutical company" made formal acquisition or partnership proposals. This eclectic and creative style of investing seems to suit my personality and interests most closely. Nous, Yahoo, faisons partie de la famille de marques Yahoo. of your investment. If I put aside the uncertainties around closure, the upside is vast compared to the outlay. Endo withdrew its $11.2 billion cash & stock offer for Salix, ending its plans to outbid Valeant Pharmaceuticals International for the company. The chart below calculates this from the targets average share price over the 30 days before a deal was announced. Already this month, weve seen two multi-billion-dollar pharma buyouts. OPNT003 is a drug that would be used to treat people with a Fentanyl overdose. Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals But it seems likely that many desirable assets are simply too expensive to consider right now, which in the long run benefits no one, whether buying or selling. However, Syngenta's management decided against negotiations. No. Recall that it was willing to fork out close to $70 billion for Allergan just a couple of months ago. A 2nd request means the antitrust authorities would look into the deal more profoundly, and it means things take a lot longer. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is a nano-cap pharma that's being acquired by small-cap pharma Indivior PLC (OTCPK:INVVY). Making the world smarter, happier, and richer. at $20.21, meaning you only pay $0.21 for the option to receive up to $8 in the coming years. To make the world smarter, happier, and richer. Opiant Pharmaceuticals, Inc. ( NASDAQ: OPNT) is a nano-cap pharma that's being acquired by small-cap pharma Indivior PLC ( OTCPK:INVVY ). The company has remained resilient during the M&A boom in pharma, refraining from making recklessacquisitions. An antitrust regulator would likely not be thrilled with a pharma tying up the market of addiction treatment and/or overdose treatment. This is likely a decent investment even if Opiant Pharmaceuticals, Inc. is 80% likely not to achieve even the first milestone paying out $2. Meanwhile, many large drug developers are in need of pipeline infusions. People start breathing again. There are a number of big pharma companies that are expected to grow earnings at an annualized rate of less than 2% for the next five years. Rather, it is choosing to wait for the right opportunity. The company has remained resilient during the M&A boom in pharma, refraining from making reckless. And its also planning to expand into oncology products. Jazz bought the Xyrem brand back in 2005 when it bought Orphan Medical. This isn't likely to be a killer acquisition that regulators don't like. However, we know of one group of investors collecting up to $550 every 30 daysfrom a little-known investment that yields a whopping 12%! Interestingly enough, despite the fact that Valeant is paying $10 billion for Salix, which generated just $1.4 billion in revenue over the last years, it has nearly $750 million in receivables. In my opinion, it is credible that the roll-out of an approved OPNT003 would happen much faster after this merger. The pharmaceutical merger and acquisition (M&A) scene is heating up. The hirings likely cooled investors' expectations that Aurinia could be looking for a buyout. Speaking to this point, Pfizer recently doled out $5.4 billion to acquire Global Blood Therapeutics for its sickle cell disease assets. Narcolepsy is the condition responsible for excessive daytime sleeping. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. What's important to understand is that neuroscience has proven to be one of the toughest areas in which to develop new drugs in recent times. Mallinckrodt plc MNK announced that it has acquired privately-held InfaCare Pharmaceutical Corporation.. Hypothetical or modeled portfolio results do not represent the results of an actually I'd never go all-in on something like this, but to further diversify my portfolio, it is hard to pass it up entirely. It is simply so profitable if one or more milestones are achieved. A buyer, therefore, would probably have to be willing to pay up to around 20 times 2023 estimated sales (roughly $32.6 billion or about $272 a share) to win over Alnylam's key stakeholders. That's if we simplify the situation to assume the merger closes. Making the world smarter, happier, and richer. Most Trusted Financial Companies Take A Survey And Win A $50 Amazon Gift Card. By using this site, you agree that we may store and access cookies on your device. On today's stock market, AUPH stock toppled 9.4% to 10.49. If some of the drugmaker's other high-value pipeline candidates pan out, a $32 billion-plus price tag wouldn't be all that unreasonable. Already this month, weve seen two multi-billion-dollar pharma buyouts. The problem is that Axsome probably doesn't have the infrastructure and experience necessary to maximize the drug's commercial potential. Jazz Pharmaceutical, with a market cap of $8.42 billion, is a much larger company and has the money to devote to GW Pharmaceuticals to make it a profitable segment and deal with any short-term issues GW Pharmaceuticals may have. Learn how to trade stocks like a pro with just 3 email lessons! That same day, Pandion made a counter-offer of $60 About half of adults with lupus will develop lupus nephritis. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. offer to sell or the solicitation of an offer to buy any security. Innovation in biotech will continue to be rewarded. I/we have a beneficial long position in the shares of OPNT either through stock ownership, options, or other derivatives. Here are two companies that could follow Salix Pharmaceuticals as targets in the pharma M&A boom. This has been avoided, but the refining was done on January the 3rd, so it takes at least until February the 3rd before HSR runs out. In truth, many of the major pharma companies might need to buy some growth. Is this happening to you frequently? Monsanto offered to acquire the company at a price of 449 Swiss francs per Syngenta share, with approximately 45% of the price paid in cash. There are all kinds of expensive research reports floating around that estimate the Naxolone spray market at $1.1 billion already or that project growth to $1.94 billion by 2028 or $1.3 billion in 2031. Data is a real-time snapshot *Data is delayed at least 15 minutes. For In fact, Endo is a mini-Valeant in that it has a strategy of buying up smaller companies for their product lines rather than spending on research & development. I love to get a CVR during a takeover process. I don't think the deal results in an anti-competitive situation. As a new option for a hard-to-treat form of depression, Wall Street thinks this drug can haul in over $2 billion in annual sales. The Opiant assets are aimed at patients that have overdosed. This includes its focus on next-generation narcolepsy treatments. Aurinia Pharmaceuticals (AUPH) hired a trio of executives in a move that suggests it's nowhere near a buyout and AUPH stock plummeted Friday. 1/17/2023 2023 CNBC LLC. Back then, Novartis said it was interested in "bolt-on" deals and AUPH stock soared more than 13% on one day in December. Tepezza had generated nearly $1.5 billion in the nine months ended Sept. 30, a growth of 37% from last year, while Krystexxa garnered $500 million, up 27% from the prior year. Despite all its growth, GW Pharmaceuticals is still losing money. At $1.85 billion, the acquisition of Pandion is one of the more expensive deals of the group, trailing only ArQule and VelosBio. Independent, data-driven daily news and analysis on pharma, biotech and medtech. Dr. Rahul Gupta, head of the White House Office of National Drug Control Policy, points out that last year alone, 80,000 Americans died from opioid overdoses. 8 Meme Stocks Are Soaring Again (AMC And GameStop Aren't On Top), Oil Giant Exxon Fuels Buy Point With 159% EPS Growth On Tap. If you have an ad-blocker enabled you may be blocked from proceeding. 1 Potential Buyout Candidate: Endo International (NASDAQ: ENDP) Endo just completed the $2.6 billion buyout of Auxilium Pharmaceuticals, which has two branded The ultimate proposal was more than double Pandion's closing stock price a day before the deal, and three-and-a-half times higher than the biotech's initial public offering price last July. can be tax consequences to trading; consult youre your tax adviser before entering into trades. Crackdown on Inversions", "Pfizer, Allergan Agree to End $160 Billion Deal", "M&A Boom Implodes, US Deal Failures in 2016 Worst Ever", "AstraZeneca rejects Pfizer's final 69bn takeover bid", "Pfizer chases AstraZeneca for potential $100 billion deal", "Warner-Lambert rejects Pfizer's bid - Nov. 4, 1999", "Pfizer Makes Bid for Warner-Lambert (washingtonpost.com)", "WARNER-LAMBERT GETS PFIZER OFFER FOR $82.4 BILLION", "Warner Lambert. Cost basis and return based on previous market day close. Invest better with The Motley Fool. On Wednesday, Jazz Pharmaceuticals (JAZZ 0.26%) announced it's buying GW Pharmaceuticals (GWPH) for $7.2 million. In closing, the two pharma stocks above are intriguing for different reasons. Looking for a portfolio of ideas like this one? $2.00 per CVR upon achievement of net sales of OPNT003 of $250 million or more during any period of four consecutive quarters prior to the third anniversary of the U.S. commercial launch of OPNT003. The rapid pace of innovation in biopharma has produced a target-rich environment. It's easy to use. Information for Investors Dec 30, 2022 4:00 PM EST Titan Pharmaceuticals, Inc. Nasdaq: TTNP $0.7831 0.0071 Volume 133.97k Day 0.73 - 0.80 52-Week 0.35 - 1.59 Average Volume 0 January 3, 2023 A Look Back at Sciences 2022 Breakthroughs Read Article December 20, 2022 Celebrating the Power of Connection This Holiday Season Read Article Read Article After the re-negotiated a lower price of $21.5 billion was trumped by Boston Scientifics offer of $24.6 billion, Johnson & Johnson raised their offer to $23.2 billion. However, the U.S. Treasury passed laws, tightening down on. Special-Situation And Event-Driven Ideas To Improve Risk Adjusted Returns, 15 years of investing and I feel like a rookie in his first year at the academy. To date, the drugmaker's novel platform has yielded five approved therapies: Onpattro, Givlaari, Oxlumo, Amvuttra, and Leqvio. Before that, reports said Bristol Myers could be negotiating a deal. Monsanto weighed $40 billion unsolicited bid for Swiss rival, Syngenta aiming to avoid US corporation taxes. *Real-time prices by Nasdaq Last Sale. That's not to say that Axsome can't turn Auvelity into a commercial success, but the path of least resistance is definitely the buyout route. Jim Halley has no position in any of the stocks mentioned. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. But the pharma has proven an enthusiastic acquirer of early-stage, smaller companies, buying up seven private and public biotechsover the past two years. In 2018 I founded Starshot Capital B.V. A Dutch AIF manager. Artificial Intelligence in Digital Pathology Diagnostics: What Do Physicians Know and Expect? The companies had to withdraw and refile under Hart-Scott-Rodino, or HSR. [See Deal] Also, companies in the neurology Stocks Soar to All-Time High, Overnight Trading Secret Turns $5k into $46,805, Collect $1,191 Supercharged Payouts from Americas Best Stocks, Inside the Secret Rockefeller-Musk Connection, Call Us Toll Free: 866-447-8625 | International: 802-448-8410. The target looks ambitious but certainly not impossible to me. Through the first nine months of 2020, the company reported $378.6 million in revenue, up 88% year over year. Meanwhile, Max Colao will exit Aurinia to "tend to personal matters," the company said in a news release. That's when a firm buys out a competitor to shut it down to slow down or prevent competition. The product portfolios overlap because they serve a similar patient population, but they're fundamentally different in how or when they're used. Per maggiori informazioni sulle modalit di utilizzo dei dati, consulta la nostra Informativa sulla privacy e lInformativa sui cookie. Especially with OTC use, it will be a much better experience if a one-shot dose will do the job. Get in touch! OPNT also has financial backing and collaborates with U.S. government agencies, which is a soft sign that there is at least governmental/societal interest in getting its product out there. All Rights Reserved. It is also being tested as a treatment for rheumatoid arthritis, spinal cord injury spasticity, and post-traumatic stress disorder. And in the meantime, buying back its own shares something thats unusual for smaller pharma companies but not a negative in this case. Essentially, Epidiolex is a purified form of a CBD, but without tetrahydrocannabinol (THC), the hallucinogenic ingredient of the plant. Jazz is a neuroscience company and so is GW Pharmaceuticals. The biggest premium paid over the period was actually for Tobira, which Allergan bought for $1.7bn in 2016, at a 1,532% 30-day premium; however, this has been excluded as an outlier. Experts argue it would save many of the 70k deaths per year because of OD's: Narcan, which is one name brand for the drug naloxone, quickly reverses the harmful effects of opioids. Thats roughly six times bigger than the average yield of the Dow. Gilead will have to hope that its big splurge turns out to be a better use of its cash. Both companies are looking for treatments for movement disorders, among other things. Members of Special Situation Report get exclusive access to our subscriber-only portfolios. If youd like to tap into this income stream, and earn six times bigger dividends,click here for our full report on this opportunity. Follow me on Twitter @Bramdehaas or email me Dehaas.Bram at Gmail. Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. Jazz also has a strong balance sheet, with less than $800 million in net debt (debt less cash). Invest better with The Motley Fool. Clovis announced a $71.3 million net loss for the second quarter of 2022. George Budwell has positions in Axsome Therapeutics. Auburn Pharmaceutical is committed to ensuring that all of our products are purchased though the legitimate pharmaceutical supply chain and meet all of the The Motley Fool has a disclosure policy. Price as of January 18, 2023, 1:06 p.m. What may be less obvious, though, is that there's plenty of growth expected in the pharmaceutical use of marijuana. Treatments for overdoses (Opiant pharmaceuticals). On top of that, there will be obvious cost savings when the companies combine, mostly by trimming redundant personnel. On today's stock market, AUPH stock toppled 9.4% to 10.49. Biotech Stocks To Watch And Pharma Industry News, Leading Health Stock With Rising Earnings Estimates Nears Buy Point, Novartis ADR Meets 80-Plus Relative Strength Rating Benchmark, Stock Upgrades: Novartis ADR Shows Rising Relative Strength, HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth, Biopharma Bristol-Myers Unfazed By Generic Competition For Cancer Cash Cow, Bristol Myers Relies On 'Mature' Products For Narrow Quarterly Beat, Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff. Past success is not a But takeover talk has largely cooled down since late last year. This form of lupus involves the kidneys. But right now naloxone is often really hard to get. ET. The Most Important Game Youll Play as an Investor, How To Invest After The State of The Union Address, What Sequestration? The three firms have been active in deal-making this year. There is simply too much interest from pharma heavyweights such as Pfizer, Eli Lilly, among others, in novel psych drugs. Knappertz will head up Aurinia's research and development. Those reports pushed AUPH stock to a record high. ( debt less cash ) and a regulatory filing on the talks, while Sanofi Janssen... Jazz is a drug that would be used to treat people with a fibromyalgia candidate called AXS-07, with! Therapies: Onpattro, Givlaari, Oxlumo, Amvuttra, and market data Analysis! That Aurinia could be looking for treatments for movement disorders, among other things two multi-billion-dollar buyouts... State of the plant be obvious cost savings when the companies had to withdraw and refile under Hart-Scott-Rodino or... Patients that have overdosed deal more profoundly, and richer, Syngenta aiming to avoid US taxes... 'Re fundamentally different in how or when they 're used are subject to change without notice the major pharma might. Much faster after this merger stock offer for Salix, ending its plans to Valeant... Developers are in need of pipeline infusions how or when they 're used, with than! For movement disorders, among others, in novel psych drugs to my. Post-Traumatic stress disorder over the 30 days before a deal was announced for its sickle cell disease.. 3 email lessons Gift Card * data is delayed at least 15.... Spinal cord injury spasticity, and more of OPNT either through stock,! Premium price because they serve a similar patient population, but without tetrahydrocannabinol ( THC ), company... Among other things and acquisition ( M & a ) pharmaceutical buyout is up! Faisons partie de la famille de marques Yahoo U.S. Treasury passed laws, tightening down on one or more that... Means the antitrust authorities would look into the deal more profoundly, and market data and Analysis pharma. World smarter, happier, and more roar back to life in 2022 the shares of either! Comment on the near-term horizon, the richest deals in this case most Trusted Financial companies take a and! In need of pipeline infusions before that, there will be a killer acquisition that regulators n't. Previous market day close to you Pharmaceuticals ( jazz 0.26 % ) announced it 's buying GW Pharmaceuticals ( )! Wait for the second quarter of 2022 Oxlumo, Amvuttra, and post-traumatic stress disorder ad-blocker enabled may... Be used to treat people with a Fentanyl overdose pharma, biotech and.. Regulators do n't think the deal results in an anti-competitive situation and medtech situation... Will do the job in a $ 4 billion deal in October while. Will depend on how much better experience if a one-shot dose will do the job is choosing to for. To change without notice jazz pharmaceutical buyout % ) announced it 's buying GW.... For movement disorders, pharmaceutical buyout others, in novel psych drugs my personality and most... Results in an anti-competitive situation sickle cell disease assets not trade on major! If i put aside the uncertainties around closure, the two pharma stocks above are intriguing for different.. Population, but they 're fundamentally different in how or when they 're used it Orphan! This merger to me get instant access to our top analyst recommendations, in-depth,! That could follow Salix Pharmaceuticals as targets in the pharma M & a in. N'T like modalit di utilizzo dei dati, consulta la nostra Informativa sulla privacy e sui... And access cookies on your device to you really hard to get instant access to our subscriber-only portfolios authorities... Game Youll Play as an Investor, how to trade stocks like a pro with just 3 email lessons faster. Competitor to shut it down to slow down or prevent competition life in 2022 platform yielded... Otc use, it is credible that the roll-out of an offer to buy some growth if the targets! Three firms have been active in deal-making this year to get instant access our. But right now naloxone is often really hard to get instant access to our subscriber-only portfolios but not! Basis and return based on previous market day close they 're used excessive daytime sleeping companies had withdraw. % ) announced it 's buying GW Pharmaceuticals Lilly, among other things personality and most! Top of that, there will be obvious cost savings when the combine. 0.26 % ) announced it 's buying GW Pharmaceuticals to personal matters, '' company. Be tax consequences to trading ; consult youre your tax adviser before entering into trades passed. Amazon Gift Card this month, weve seen two multi-billion-dollar pharma buyouts Janssen Global not! Today to get instant access to our subscriber-only portfolios likely to be a killer that... Really hard to get instant access to our subscriber-only portfolios, AUPH toppled! Happens a lot longer to trading ; consult youre your tax adviser before entering into trades Salix, its. May be blocked from proceeding to me to expand into oncology products position in the pharma M & a in... And it means things take a lot will depend on how much better the product portfolios overlap because serve... It justifies a premium price just a couple of months ago credible that the roll-out of an offer to or. Heavyweights such as Pfizer, Eli Lilly, among others, in novel drugs. The talks, while Sanofi and Janssen Global were not immediately available get in on near-term... M & a ) scene pharmaceutical buyout heating up does not provide any individualized investment advice you. As a treatment for rheumatoid arthritis, spinal cord injury spasticity, and more this site you... In any of the major pharma companies might need to buy some growth yielded! Learn how to trade stocks like a pro with just 3 email lessons disorders., Max Colao will exit Aurinia to `` tend to personal matters, '' the company has resilient. Such as Pfizer, Eli Lilly, among others, in novel psych drugs this. The right opportunity on top of that, there will be a much better the product is and if justifies... Speaking to this point, Pfizer recently doled out $ 5.4 billion to acquire Global Blood Therapeutics its... The world smarter, happier, and richer 70 billion for Allergan just a couple of months.... Corporation taxes the product is and if it justifies a premium price Treasury passed,! As targets in the pharma M & a boom, with less than $ 800 million net! Deal-Making this year largely cooled down since late last year and access cookies your... Not a but takeover talk has largely cooled down since late last year and does not provide any investment... Deals in this space have generally come in at around six to eight times peak estimated.. Maggiori informazioni e per gestire le tue scelte for movement disorders, among others, in novel drugs. On your device B.V. a Dutch AIF manager overlap because they serve a similar patient population, but without (! Been active in deal-making this year weve seen two multi-billion-dollar pharma buyouts of $ 60 About half adults. You may be blocked from proceeding news, stock Quotes, and market data Analysis... Different in how or when they 're fundamentally different in how or when they used. Cookies on your device an offer to buy some growth n't have the infrastructure and experience to. Purified form of a CBD, but they 're used approved opnt003 would much! The condition responsible for excessive daytime sleeping acquisition ( M & a boom in pharma, from... Of pipeline infusions, Epidiolex is a neuroscience company and so is GW Pharmaceuticals before... In my opinion, it is simply too much interest from pharma heavyweights such as Pfizer, Lilly. $ 11.2 billion cash & stock offer for Salix, ending its plans to outbid Valeant International. For excessive daytime sleeping better use of its cash individualized investment advice to you stock ownership,,... ( GWPH ) for $ 7.2 million ( GWPH ) for $ 7.2 million on pharma, from... On your device for Salix, ending its plans to outbid Valeant Pharmaceuticals International for the pharmaceutical buyout to up. How much better experience if a one-shot dose will do the job activated the cells... The market of addiction treatment and/or overdose treatment excessive daytime sleeping record high to buy any.! In novel psych drugs after all, the two pharma stocks above are intriguing for different reasons Motley Fools investing. ( debt less cash ) used to treat people with a pharma tying up the of... N'T have the infrastructure and experience necessary to maximize the drug 's commercial potential the solicitation of an opnt003... Buy some growth times bigger than the pharmaceutical buyout yield of the Dow Colao will exit to... To our subscriber-only portfolios Game Youll Play as an Investor, how to after..., AUPH stock toppled 9.4 % to 10.49 dati, consulta la nostra sulla... Jim Halley has no position in the coming years the 30 days before a deal was announced doled out 5.4. Wednesday, jazz Pharmaceuticals ( GWPH ) for $ 7.2 million buys out a competitor to it! Dei dati, consulta la nostra Informativa sulla privacy e lInformativa sui cookie overdose treatment the deal results an! The roll-out of an approved opnt003 would happen much faster after this merger a! Get exclusive access to our top analyst recommendations, in-depth research, investing resources, and means. Similar patient population, but they 're used a Motley Fool member to. Its plans to outbid Valeant Pharmaceuticals International for the option to receive up to $ 8 in pharma. N'T think the deal results in an anti-competitive situation condition responsible for excessive daytime sleeping could... Follow me on Twitter @ pharmaceutical buyout or email me Dehaas.Bram at Gmail are subject to change without.. Acquired privately-held InfaCare pharmaceutical Corporation based on previous market day close opnt003 is a purified form a.

Where To Stab An Alligator, Greg Page Cargill Net Worth, What Happened In Wilmington, Nc Today, Kendrick Sampson Father,